Alessandra Fierabracci

Prof. Alessandra Fierabracci

Infectivology and Clinical Trials Research Department, Children's Hospital Bambino Gesù, Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Autoimmunity Reviews
Verified
Journal Article
Closed access
EGElena Gianchecchi
Elena Gianchecchi
DDDomenico Vittorio Delfino
Domenico Vittorio Delfino
AFAlessandra Fierabracci
Alessandra Fierabracci

Verified
Journal Article
Open access
PDF file
SESharon Eleuteri
Sharon Eleuteri
AFAlessandra Fierabracci
Alessandra Fierabracci
Mesenchymal stem cells (MSCs) have regenerative, immunoregulatory properties and can be easily isolated and expanded in vitro. Despite being a powerful tool for clinical applications, they present limitations in terms of delivery, safety, and variability of therapeutic response. Interestingly, the MSC secretome composed by cytokines, chemokines, growth factors, proteins, and extracellular vesicles, could represent a valid alternative to their use. It is noteworthy that MSC-derived extracellular vesicles (MSC-EVs) have the same effect and could be advantageous compared to the parental cells because of their specific miRNAs load. MiRNAs could be useful both in diagnostic procedures such as “liquid biopsy” to identify early pathologies and in the therapeutic field. Not only are MSC-EVs’ preservation, transfer, and production easier, but their administration is also safer, hence some clinical trials are ongoing. However, much effort is required to improve the characterization of EVs to avoid artifacts and guarantee reproducibility of the studies.

1 December 2015 in Cell Transplantation
Verified
Journal Article
Open access
ANDREA DEL FATTOREANDREA DEL FATTORE
ANDREA DEL FATTORE
RLRosa Luciano
Rosa Luciano
LPLuisa Pascucci
Luisa Pascucci
BGBianca Maria Goffredo
Bianca Maria Goffredo
EGEzio Giorda
Ezio Giorda
MMMaurizio Muraca
Maurizio Muraca
The immunomodulatory activity of mesenchymal stem cells (MSCs) is largely mediated by paracrine factors. We have recently shown that the immunosuppressive effects of MSCs on B lymphocytes in peripheral blood mononuclear cell (PBMC) culture can be reproduced by extracellular vesicles (EVs) isolated from MSC culture supernatants. Here we investigated the effect of bone marrow-derived MSC-EVs on T cells on PBMC cultures stimulated with anti-CD3/CD28 beads. Stimulation increased the number of proliferating CD3+ cells as well as of regulatory T cells (Tregs). Coculture with MSCs inhibited the proliferation of CD3+ cells, with no significant changes in apoptosis. Addition of MSC-EVs to PBMCs did not affect proliferation of CD3+ cells, but induced the apoptosis of CD3+ cells and of the CD4+ subpopulation and increased the proliferation and the apoptosis of Tregs. Moreover, MSC-EV treatment increased the Treg/Teff ratio and the immunosuppressive cytokine IL-10 concentration in culture medium. The activity of indoleamine 2,3-dioxygenase (IDO), an established mediator of MSC immunosuppressive effects, was increased in supernatants of PBMCs cocultured with MSCs, but was not affected by the presence of MSC-EVs. MSC-EVs demonstrate immunomodulatory effects on T cells in vitro. However, these effects and the underlying mechanisms appear to be different from those exhibited by their cells of origin.

17 October 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
EGElena Gianchecchi
Elena Gianchecchi
AFAlessandra Fierabracci
Alessandra Fierabracci
Regulatory T (Treg) cells represent a subpopulation of suppressor CD4+ T cells critically involved in the establishment of peripheral tolerance through the inhibition of effector T (Teff) cells and the suppression of the immune-mediated tissue destruction toward self-antigens. Treg generation, their suppressive properties and also Treg-Teff cell interactions could be modulated at least in part by programmed cell death-1 (PD-1) expression on their surface and through binding between PD-1 and programmed cell death ligand-1 (PD-L1). Defects involving PD-1 and Tregs can lead to the development of pathological conditions, including autoimmune disorders or promote cancer progression by favoring tumor evasion from the host immune response. At the same time, PD-1 and Tregs could represent attractive targets for treatment, as demonstrated by the therapeutic blockade of PD-L1 applied for the management of different cancer conditions in humans. In the present Review, we focus specifically the role of PD-1/PD-L1 on Treg development and activity.

21 November 2014 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
ANDREA DEL FATTOREANDREA DEL FATTORE
ANDREA DEL FATTORE
RLRosa Luciano
Rosa Luciano
RSRossana Saracino
Rossana Saracino
GBGiulia Battafarano
Giulia Battafarano
CRCristiano Rizzo
Cristiano Rizzo
MMMaurizio Muraca
Maurizio Muraca
Malignant glial tumors, including glioblastoma multiforme, account for 15 - 20% of pediatric CNS malignancies. They are most resistant to therapy and are associated with a poor prognosis. Given the ability of mesenchymal stem cells (MSCs) to affect glioma growth, we investigated the effects of extracellular vesicles (EVs) derived from MSCs on U87MG glioblastoma cells line. EVs were isolated from culture media of MSCs from different sources, including bone marrow (BM), umbilical cord (UC) and adipose tissue (AT) and added to U87MG culture. The internalization and the effects of BM-, UC- and AT-MSC-EVs on proliferation and apoptosis of tumor cells were evaluated. Both confocal microscopy and FACS analysis showed internalization of EVs into tumor cells. BM- and UC-MSC-EVs decreased cell proliferation, while an opposite effect was observed with AT-MSC-EVs. Moreover, both BM- and UC-MSC-EVs induced apoptosis of glioblastoma cells, while AT-MSC-EVs had no effect. Loading UC-MSC-EVs with Vincristine further increased cytotoxicity when compared both to the free drug and to untreated EVs. Different effects of MSC-EVs on cancer cells were observed depending on their tissue of origin. Moreover, MSC-EVs can deliver antiblastic drugs to glioblastoma cells.

1 February 2018 in Autoimmunity Reviews
Verified
Journal Article
Closed access
EGElena Gianchecchi
Elena Gianchecchi
DDDomenico Vittorio Delfino
Domenico Vittorio Delfino
AFAlessandra Fierabracci
Alessandra Fierabracci